ENDRA Life Sciences Inc
NASDAQ:NDRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ENDRA Life Sciences Inc
Other Current Assets
ENDRA Life Sciences Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Other Current Assets
$254.7k
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Current Assets
$960m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
1%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Other Current Assets
$474.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Current Assets
$1.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Current Assets
$2.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Current Assets
$376.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
See Also
What is ENDRA Life Sciences Inc's Other Current Assets?
Other Current Assets
254.7k
USD
Based on the financial report for Sep 30, 2025, ENDRA Life Sciences Inc's Other Current Assets amounts to 254.7k USD.
What is ENDRA Life Sciences Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-17%
Over the last year, the Other Current Assets growth was 17%. The average annual Other Current Assets growth rates for ENDRA Life Sciences Inc have been -35% over the past three years , -17% over the past five years .
